What Is CJC-1295 Without DAC?
CJC-1295 Without DAC — also referred to as Modified GRF (1-29) or Mod GRF 1-29 — is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). The “Without DAC” designation distinguishes it from CJC-1295 With DAC (Drug Affinity Complex), a version engineered for prolonged half-life through albumin binding. Without the DAC modification, CJC-1295 No DAC has a half-life of approximately 30 minutes, producing a more physiological GH pulse profile compared to the extended-release DAC version.
CJC-1295 Without DAC acts on the GHRH receptor in the anterior pituitary, stimulating GH synthesis and secretion. It is most frequently studied in combination with ipamorelin, a selective ghrelin receptor agonist, to simultaneously engage both GH secretagogue receptor pathways for synergistic GH release in research models.
CJC-1295 Without DAC vs. With DAC — Key Distinction
Understanding this distinction is critical for research design:
| Feature | CJC-1295 Without DAC | CJC-1295 With DAC |
|---|---|---|
| Also known as | Modified GRF 1-29, Mod GRF 1-29 | CJC-1295 DAC |
| Half-life | ~30 minutes | ~6–8 days |
| GH release pattern | Pulsatile (physiological) | Prolonged bleed (non-pulsatile) |
| Mechanism of longevity | Improved sequence stability only | Albumin binding via DAC technology |
| Research preference | Studies requiring pulsatile GH mimicry | Studies requiring sustained GH elevation |
CJC-1295 Mechanism of Action
- GHRH receptor agonism: Binds and activates GHRH receptors on pituitary somatotroph cells, stimulating GH gene transcription and secretion
- Synergy with GHRPs: GHRH receptor activation and ghrelin receptor (GHSR-1a) activation are complementary — co-administration with ipamorelin produces GH release greater than either compound alone in research models
- Somatostatin inhibition: Hypothalamic signaling from GHRH receptor activation may also suppress somatostatin tone, further amplifying GH secretion in the pulse window
- IGF-1 upregulation: GH elevation stimulates hepatic IGF-1 synthesis, with downstream anabolic and metabolic effects studied in body composition and aging research models
CJC-1295 Without DAC Research Data
- GH pharmacokinetics: Published studies confirm CJC-1295 Without DAC produces a rapid, transient GH pulse within 15–30 minutes of administration, with return to baseline within 2–3 hours — closely mimicking endogenous GH pulse kinetics
- Combination synergy: Rodent studies demonstrate ipamorelin + CJC-1295 No DAC co-administration produces significantly greater GH area-under-the-curve than either compound alone, consistent with dual-pathway receptor activation
- Body composition: Animal studies show the ipamorelin/CJC-1295 combination increases lean mass and reduces fat mass over extended protocols, proportionate to GH and IGF-1 elevation
- Bone density: Preclinical data in aged rodents demonstrates GH secretagogue combinations preserve bone mineral density and stimulate osteoblast activity markers
CJC-1295 Without DAC Dosage Reference
| Research Context | Dose Range from Literature | Route |
|---|---|---|
| GH pulse studies (rodent) | 10–100 mcg/kg | Subcutaneous or IV |
| Combination protocols (ipamorelin + CJC) | Equal-ratio blends, varies by model | Subcutaneous |
| Body composition (rodent, chronic) | 50–200 mcg/kg/day | Subcutaneous |
Literature data provided for research reference only. Not dosing guidance for human use.
Side Effects from Research Data
- Transient flushing or warmth following administration in human volunteer data
- Mild headache reported in some subjects
- Water retention at higher doses (GH-mediated)
- No significant hormonal side effects outside the GH/IGF-1 axis at research doses
Where to Buy CJC-1295 for Research
CJC-1295 Without DAC’s four-amino acid substitutions versus native GHRH (1-29) require MS/MS verification to confirm correct sequence. Key supplier criteria:
- HPLC purity ≥99% with batch-specific certificate
- MS/MS sequence verification confirming the four stabilizing substitutions
- Third-party independent COA
- Clear labeling distinguishing No DAC from DAC variant
Core Power Peptides supplies the Ipamorelin / CJC-1295 No DAC 10mg blend at ≥99% purity per component, HPLC and MS/MS verified per batch, with third-party COA on request.
Research Disclaimer: All information on this page is for educational and scientific reference purposes only. CJC-1295 is not approved for human use. This product is sold strictly for in vitro research and laboratory use only. Not for human consumption. Not medical advice.